Print

Inhibitex, Inc. (INHX) Reports Third Quarter Financial Results and Recent Corporate Developments  
11/4/2011 7:02:10 AM

ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ:INHX, the “Company”) today announced its financial results for the third quarter ended September 30, 2011 and provided an update on several recent corporate developments, including top-line safety and antiviral data from the first cohort in its ongoing clinical trial designed to evaluate higher doses of INX-189, an oral nucleotide polymerase inhibitor, being developed to treat chronic infections caused by hepatitis C virus (HCV), administered as monotherapy or in combination with ribavirin for seven days.
//-->